Ambarella Introduces CV5 High Performance AI Vision Processor for Single 8K and Multi-Imager AI Cameras
11.1.2021 13:00:00 EET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an AI vision silicon company, today unveiled CV5, an artificial intelligence (AI) vision processor capable of recording 8K video or four 4K video streams. The new system on chip (SoC) will enable the development of intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. It combines Ambarella’s powerful CVflow AI engine with dual Arm® A76 CPUs to provide the performance necessary for a wide range of AI-based algorithms. Its advanced image signal processor (ISP) can simultaneously process images for both human viewing and machine processing. Fabricated in advanced 5 nm process technology, CV5 consumes under 2 watts of power while encoding full 8K video at 30 frames per second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005235/en/
Ambarella today unveiled the CV5 AI vision CVflow® 5 nm processor for single 8K and multi-imager AI cameras, setting a new standard for power efficiency with 8K video recording in under 2 watts. The SoC targets intelligent automotive camera systems, consumer cameras (drone, action, and 360°), and robotic cameras. (Photo: Business Wire)
“With the introduction of CV5, Ambarella is defining the next generation of automotive, consumer, and robotic cameras,” said Fermi Wang, CEO of Ambarella. “By combining 8K single-channel and 4K multi-channel recording with the high performance of our CVflow AI engine, we are enabling cameras with the highest-quality imaging and innovative new AI features.”
In automotive video telematics applications, CV5 provides the performance necessary to encode multiple video streams from front ADAS, driver monitoring, cabin monitoring, and side-view cameras. Its CVflow AI engine can simultaneously run advanced driver assistance systems (ADAS) algorithms such as lane departure, and forward collision warning as well as driver monitoring algorithms such as drowsy driver detection. The combination of high-resolution video capture with advanced AI processing enables ADAS cameras to recognize images over long distances and with high accuracy.
The exceptionally low power consumption of the CV5 SoC also makes it an ideal solution for the next generation of high resolution and high frame-rate action, 360°, and virtual reality (VR) cameras, offering 8K recording and playback in very small form factor designs.
In robotic and drone applications, CV5’s CVflow AI engine can accelerate simultaneous localization and mapping (SLAM), path planning, and obstacle detection, and avoidance algorithms for navigation and autonomous operation. For drone-based aerial videography and cinematography, CV5 can simultaneously perform flight control and navigation functions while recording up to 8K resolution video recording at 60 frames per second.
The CV5 SoC shares common SDK and computer vision (CV) tools with Ambarella’s other CVflow SoC families, simplifying development of cameras with multiple price and performance options. A complete set of CV tools helps customers port their own neural networks onto CV5, including a compiler, debugger, and support for industry-standard machine learning frameworks, such as PyTorch™, ONNX™, Caffe™, and TensorFlow™, as well as extensive guidelines for convolutional neural network (CNN) performance optimization.
CV5 SoC key features:
- CVflow architecture with DNN support
- Dual-core Arm® Cortex®-A76 up to 1.6 GHz with NEON™ DSP extensions and FPU
- High-speed SLVS-EC, MIPI-CSI (C/D PHY) interfaces, connecting up to 14 cameras
- Multi-channel ISP with up to 8KP60 throughput
- Native support for RGGB, RCCB, RCCC, RGB-IR, and monochrome sensor formats
- Multi-exposure high dynamic range (HDR) processing
- Real-time, hardware-accelerated fisheye dewarping and lens distortion correction (LDC)
- AVC and HEVC encoding with up to 8KP60 throughput and multiple stream support
- Rich set of interfaces includes 4-lane PCIe, CAN FD, Gigabit Ethernet, USB 3.1 host and device, three SD card controllers, MIPI DSI/CSI-2 and HDMI video outputs
- LPDDR4x / LPDDR5 / LPDDR5x support, 64-bit data bus and up to 32 GB capacity
- Advanced security features, including secure boot with TrustZone® and secure memory, TRNG, OTP, DRAM scrambling and virtualization
- 5 nm process technology
- 16x16 FBGA package with 0.5 mm ball pitch
About Ambarella, Inc.
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. © 2021 Ambarella, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005235/en/
Contact information
Ambarella Contact: www.ambarella.com/about/contact/inquiries
Media Contact: Molly McCarthy, Valley Public Relations, mmccarthy@ambarella.com
Investor Relations Contact: Louis Gerhardy, Ambarella, lgerhardy@ambarella.com, (408) 636-2310
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
